Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | FABP1 | P07148 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517768 | 0.98 | KDM4E (0.49) | KDM4EMAPTCYP1A2PTPN1TBXA2R | |
| SCHEMBL12697756 | 0.94 | KDM4E (0.50) | KDM4EMAPTCYP1A2PTPN1TBXA2R | |
| SCHEMBL5513972 | 0.89 | LMNA (0.54) | KDM4EMAPTCYP1A2PTPN1TBXA2R | |
| SCHEMBL8882025 | 0.85 | PTPN1 (0.62) | MAPTPTPN1ALDH1A1CYP3A4TSHR | |
| SCHEMBL2271444 | 0.84 | PTPN1 (0.61) | MAPTPTPN1ALDH1A1CYP3A4TSHR | |
| SCHEMBL27480442 | 0.83 | PTPN1 (0.60) | KDM4EMAPTCYP1A2PTPN1ALDH1A1 | |
| SCHEMBL6042801 | 0.83 | PTPN1 (0.51) | KDM4EMAPTCYP1A2PTPN1ALDH1A1 | |
| SCHEMBL8881039 | 0.81 | PTPN1 (0.55) | KDM4EMAPTCYP1A2PTPN1ALDH1A1 | |
| SCHEMBL1138239 | 0.81 | KDM4E (0.50) | KDM4EMAPTCYP1A2PTPN1ALDH1A1 | |
| SCHEMBL8882396 | 0.81 | ASPH (0.50) | KDM4EMAPTPTPN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673284-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2673284-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2880123-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2880123-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-9403859-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403859-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403859-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160145281-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145281-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145281-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20150140682-A1 | IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-05-21 | — | — | US | disclosed |
| US-8835637-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835637-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835637-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014019707-A2 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019707-A2 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| EP-2673284-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | Roche Diagnostics GmbH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-20130323719-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2012107419-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012107419-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150140682-A1 | IRIDIUM-BASED COMPLEXES FOR ECL | ALPL, LIG3, SOD3 | KDM4E 4465/4885MAPT 4186/4885CYP1A2 3078/4885 |
| US-20160145281-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ALPL, LIG3, SOD3 | KDM4E 4590/4885MAPT 4265/4885CYP1A2 3405/4885 |
| US-20130323719-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ALPL, LIG3, SOD3 | KDM4E 4590/4885MAPT 4265/4885CYP1A2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.